These results suggest a role for the tyrosine kinase-independent actions of DDR2 in regulating breast cancer metastasis and could explain, in part, the ineffective responses to TKI therapies in aggressive late-stage breast cancer patients. Here, DDR2 is linked to breast carcinoma.